Yael Kopleman

Learn More
PURPOSE The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug against KRAS(G12D) along four months. This novel siRNA based drug was studied, in combination with chemotherapy, as targeted therapy for Locally Advanced Pancreatic Cancer (LAPC). METHODS An open-label Phase 1/2a study in the first-line setting of(More)
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. AbstrAct Purpose: The miniature biodegradable implant siG12D-LODER™ was inserted into a tumor and released a siRNA drug(More)
  • 1